Might CAR-NK –Based Immunotherapy Be More Effective, Less Toxic?
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell –based immunotherapies. (Source: CancerNetwork)
Source: CancerNetwork - July 22, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Pancreatic Tumor Signal Blocks T-Cell Infiltration, Immunotherapy
“Tumor cell–intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy,” the lead study author concluded. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Does Immunotherapy Have a Role in EGFR-Mutant Lung Cancer? Does Immunotherapy Have a Role in EGFR-Mutant Lung Cancer?
Three thoracic oncology experts discuss the evolving role of immunotherapy and combination therapies in driver-mutation-positive lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Roche takes Tecentriq hit on survival data
Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche still awaiting Tecentriq survival data in key study
Roche's Tecentric immunotherapy mixed with chemotherapy has not yet achieved a hoped-for overall survival target in first-line lung cancer treatment, the Swiss drugmaker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Survival Benefit From Immunotherapy With Modified Poliovirus in Recurrent Glioblastoma?
A noncontrolled phase I study in recurrent metastatic glioblastoma showed 3-year survival was five times higher in patients treated with intratumoral PVSRIPO. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Immunotherapy Ups Survival Even in Melanoma With Brain Mets Immunotherapy Ups Survival Even in Melanoma With Brain Mets
The use of checkpoint inhibitors significantly improved overall survival and the rate of 4-year survival in patients with stage IV melanoma with brain metastases.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Narjust Duma on How Gender Affects the Tolerability of Immunotherapy
In this interview, we discuss a study of sex differences in the tolerability of anti –programmed death 1 immunotherapy among patients with metastatic melanoma. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Narjust Duma, MD Source Type: news

Study finds melanoma biomarkers predicting checkpoint blocker response
(Dana-Farber Cancer Institute) Scientists at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 18, 2018 Category: Cancer & Oncology Source Type: news

Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma
Dr Jeffrey Weber discusses the results of the KEYNOTE-054 trial, which demonstrated clear benefit with adjuvant pembrolizumab in patients with stage III resected melanoma.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Insurers And Government Are Slow To Cover Expensive CAR-T Cancer Therapy
Treatment costs for the immunotherapy can run to more than $1 million. Some state Medicaid programs aren't paying for the treatment, and Medicare's complicated payment rates have hospitals worried.(Image credit: Fanatic Studio/Collection Mix: Subjects RF/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - July 17, 2018 Category: Consumer Health News Authors: Michelle Andrews Source Type: news

Society for Immunotherapy of Cancer Publishes First Clinical...
The Society for Immunotherapy of Cancer (SITC) published the first clinical immunotherapy treatment guidelines for non-small cell lung cancer today, providing oncologists and other advance practice...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/07/prweb15632725.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 17, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Melanoma: Immunotherapy for brain metastases 'doubles survival'
A new study into U.S. cancer data finds that checkpoint blockade immunotherapy doubles median overall survival in melanoma patients with brain metastases. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 13, 2018 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Genmab, Immatics partner on cancer immunotherapy
Germany-based Immatics Biotechnologies has entered into a research collaboration and license agreement with Danish biotech, Genmab. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 13, 2018 Category: Pharmaceuticals Source Type: news

‘Highjack’ Autoimmunity to Enhance Efficacy of Immunotherapy?
Overexpression ofIKZF1 facilitates immune attack on skin cancer and other solid tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Electric Shock Allows for CRISPR Gene Editing Without a Viral Vector
Brief electroporation appears to make T cells more receptive to new genetic material, which could speed the development of immunotherapies. (Source: The Scientist)
Source: The Scientist - July 12, 2018 Category: Science Tags: News & Opinion Source Type: news

There ’s More Good News About Immune Therapies for Cancer
There has been welcome excitement in the cancer field lately about immune-based treatments, which co-opt the body’s own immune system to fight tumors. The so-called immunotherapies have transformed everything from solid cancers like melanoma and lung, to blood cancers like lymphoma and leukemia. In the latest study involving one of the first immunotherapies approved by the Food and Drug Administration, researchers report that an immune-based approach can even help people with advanced melanoma, which has spread to the brain, to live longer. The study, published in Cancer Immunology Research, included more than 2,700 ...
Source: TIME: Health - July 12, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Innovation Health Source Type: news

Beckman Coulter Life Sciences: CRISPR 101
How CRISPR plays an important role in immunotherapy (Source: The Scientist)
Source: The Scientist - July 12, 2018 Category: Science Tags: Sponsored Videos Source Type: news

Health Highlights: July 12, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: New Cancer Immunotherapy Technique Could be'Game Changer' A new approach to immune therapy for cancer could be a " game changer. " Currently,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 12, 2018 Category: General Medicine Source Type: news

New Cancer Immunotherapy Technique Could be 'Game Changer'
Title: New Cancer Immunotherapy Technique Could be 'Game Changer'Category: Health NewsCreated: 7/12/2018 12:00:00 AMLast Editorial Review: 7/12/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 12, 2018 Category: Cancer & Oncology Source Type: news

Immunotherapy doubles survival rates for patients with melanoma brain metastases
(Brigham and Women's Hospital) A new study evaluates data from more than 1,500 cancer programs across the country to determine the effectiveness of checkpoint blockade immunotherapies, finding that these therapies provided significant improvements in overall survival for patients with melanoma brain metastases. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2018 Category: Biology Source Type: news

New perspective on tumor genome evolution
(Center for Genomic Regulation) An interdisciplinary team of scientists at the Centre for Genomic Regulation in Barcelona, Spain, deepens understanding of tumor genome evolution and suggests negative selection acting on cancer-essential genes plays a more important role than previously anticipated. Their work, published in Genome Biology, also provides new insights for improving cancer immunotherapies in the future. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2018 Category: International Medicine & Public Health Source Type: news

Immunotherapy associated with improved survival for patients with melanoma brain metastases
(American Association for Cancer Research) Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2018 Category: Cancer & Oncology Source Type: news

American Society of Hematology hosts landmark Summit on Emerging Immunotherapies
(American Society of Hematology) Today, the American Society of Hematology (ASH) will convene laboratory investigators, clinical researchers, regulators, patient advocates, and industry leaders in Washington, D.C., for the ASH Summit on Emerging Immunotherapies for Hematologic Diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2018 Category: International Medicine & Public Health Source Type: news

Dartmouth + Innovation + Cancer
Many discoveries now revolutionizing the prevention and treatment of cancer can be traced back to Dartmouth—including immunotherapies for solid tumors, the integration of palliative care with cancer care, and the identification of cancer risks from environmental toxins and behaviors. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - July 11, 2018 Category: Hospital Management Authors: Geisel Communications Tags: Donor Impact Insider News Research campaign cancer Home-feature Interaction Norris Cotton Cancer Center Source Type: news

Swift Gene-Editing Method May Revolutionize Treatments for Cancer and Infectious Diseases
Scientists report that they have discovered a way to tweak genes in the body ’ s immune cells by using electrical fields. (Source: NYT Health)
Source: NYT Health - July 11, 2018 Category: Consumer Health News Authors: GINA KOLATA Tags: Genetic Engineering Immune System DNA (Deoxyribonucleic Acid) Immunotherapy Nature (Journal) Crispr (DNA) Source Type: news

Targeting tumor-associated acidity in cancer immunotherapy
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news

Could this system make more kidneys, livers usable for transplant?
An Italian startup has teamed with critical-care immunotherapy company CytoSorbents Corporation (NASDAQ: CTSO) on an integrated ex-vivo system to perfuse, cleanse, recondition and preserve harvested kidneys and livers — including those that are usually discarded. Aferetica srl (Mirandola, Italy) designed its PerLife system is to improve organ function and viability while reducing the risk of primary graft failure and organ rejection. PerLife incorporates CytoSorbents’ PerSorb sorbent cartridge, which uses adsorptive porous polymer technology to reduce a broad range of toxins that c...
Source: Mass Device - July 10, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Transplants Aferetica srl CytoSorbents Corp. Source Type: news

Immunotherapy in Thymic Epithelial Tumors --'Risky Business'? Immunotherapy in Thymic Epithelial Tumors --'Risky Business'?
Pembrolizumab showed encouraging antitumor activity in patients with advanced thymic epithelial tumors, but also a high rate of severe immune-related adverse events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Surgery Plus HIPEC Only ‘ Potential for Cure ’ of Peritoneal Mesothelioma
This study contributes to a better understanding of how CRS and HIPEC work and who is likely to receive the best benefit from this combination treatment. For patients with the most aggressive peritoneal mesothelioma cancers, additional options — such as immunotherapy or ongoing, post-surgical delivery of chemotherapy into the peritoneal cavity — may be additional treatments to consider. The post Surgery Plus HIPEC Only ‘Potential for Cure’ of Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 10, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

NYC biotech company gets license for cancer-fighting technology
BioVaxys, a biotechnology company with offices in New York and Radnor, has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially treat ovarian cancer, melanoma, and other solid tumor types. Financial terms of the deal are being kept confidential. “Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,”… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 10, 2018 Category: Health Management Authors: John George Source Type: news

NYC biotech company gets license for cancer-fighting technology
BioVaxys, a biotechnology company with offices in New York and Radnor, has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially treat ovarian cancer, melanoma, and other solid tumor types. Financial terms of the deal are being kept confidential. “Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 10, 2018 Category: Biotechnology Authors: John George Source Type: news

Medical News Today: 'Backpacked drugs' can boost immunotherapy for solid tumors
Researchers have designed a drug-carrying nanoparticle capable of enhancing the effect of immune cells on solid cancer tumors without harmful side effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Biologists discover process that neutralizes tumors
(University of California - San Diego) Researchers discovered an unexpected twist in the tumor vs. T cell battle. Tumors employ a protein called PD-L1 to blind T cells from carrying out their functions. PD-L1 protects tumors through a 'molecular brake' known as PD-1. Researchers have found that some tumor cells display not only their PD-L1 weapon, but also the PD-1 'brake,' essentially a neutralizing function. The unexpected mechanism that could help determine whether a cancer patient will respond to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2018 Category: Cancer & Oncology Source Type: news

Biodesix Deal Adds to Active M & amp;A Day for Medtech
Biodesix made a move to expand its lung testing franchise on a day already buzzing with M&A activity. The Boulder, CO-based company said it was acquiring Integrated Diagnostics for an undisclosed sum. The agreement includes the XL2 test, Seattle, WA-based lead oncology product, which offers a noninvasive means of ruling out cancer for patients with suspicious lung nodules. The XL2 test, which requires a simple blood draw, is a pulmonary nodule classifier that measures proteins to identify lung nodules that have a high probability of being benign. “The team at Indi has developed and substantially validated an impo...
Source: MDDI - July 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Improved Outcomes for Melanoma Brain Metastases With Added Immunotherapy
Immune checkpoint inhibitors initiated soon before or after radiosurgery offer excellent outcomes in patients with brain metastases originating from melanoma. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

N.Y. biotech firm obtains license from Jefferson for cancer-fighting technology
BioVaxys, a biotechnology company with offices in New York and Radnor has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially to treat ovarian cancer, melanoma, and other solid tumor types. Financial terms of the deal are being kept confidential. “Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,”… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 9, 2018 Category: American Health Authors: John George Source Type: news

N.Y. biotech firm obtains license from Jefferson for cancer-fighting technology
BioVaxys, a biotechnology company with offices in New York and Radnor has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially to treat ovarian cancer, melanoma, and other solid tumor types. Financial terms of the deal are being kept confidential. “Jefferson is extremely excited about the merging of this potentially lifesaving technology with the excellent team of scientists and business leaders at BioVaxys,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 9, 2018 Category: Biotechnology Authors: John George Source Type: news

Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
More and more researchers are conducting clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments. (Source: The Scientist)
Source: The Scientist - July 9, 2018 Category: Science Tags: Infographics Source Type: news

Brain cancer: Typical mutation in cancer cells stifles immune response
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report. It thus blocks the body's immune response in the battle against the mutant molecule and also impedes immunotherapy against brain cancer. This findingsuggests that rethinking antitumor immunotherapy is required. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Cancer Treatment Less Effective in Older Patients
As age increases, so does the risk for cancer. More than half of all cancer cases occur in people over 65. This is especially true for mesothelioma. The average age at diagnosis for pleural mesothelioma — the most common form of the disease — is 69. Despite cancer being more common among the elderly, many cancer treatments work best in younger patients. Researchers now have an idea of why certain cancer treatments don’t work as well in older patients. These important findings were published in June in the medical journal Cell Reports. “While it is clear that primary T cell responses decline in the ...
Source: Asbestos and Mesothelioma News - July 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Immunotherapy can fight deadly superbugs as well as cancer
A new study by Lehigh University offers an alternative that some hail as a breakthrough: training the immune system to kill the bacteria, using the same premise that has been successful in cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2018 Category: Consumer Health News Source Type: news

Viral immunotherapy to treat brain tumors in children shows promise
A viral immunotherapy using a herpes virus to treat brain tumors has been shown to be safe and well-tolerated in a pediatric study from UAB and Children ’s of Alabama.  The findings managed to show preliminary evidence of effectiveness in killing malignant tumor cells.  The funding to develop the therapy has been provided by the NIH/NCI, Department of Defense, St. Baldrick’s Foundation, Rally Foundation for Childhood Cancer Research, Cannonb all Kid’s Foundation, Hyundai Hope on Wheels, Vs.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 5, 2018 Category: Pharmaceuticals Authors: Tyler Patchen Source Type: news

Viral immunotherapy to treat brain tumors in children shows promise
A viral immunotherapy using a herpes virus to treat brain tumors has been shown to be safe and well-tolerated in a pediatric study from UAB and Children ’s of Alabama.  The findings managed to show preliminary evidence of effectiveness in killing malignant tumor cells.  The funding to develop the therapy has been provided by the NIH/NCI, Department of Defense, St. Baldrick’s Foundation, Rally Foundation for Childhood Cancer Research, Cannonb all Kid’s Foundation, Hyundai Hope on Wheels, Vs.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 5, 2018 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Immunotherapy for deadly bacteria shows early promise
(Lehigh University) Lehigh University's Marcos Pires and his team have designed a strategy aimed at tagging Gram-negative bacteria for destruction via small molecule conjugates they have created that specifically home to bacterial cell surfaces and trigger an immune response. They observed a significant decrease in the number of live bacteria using their compound in experiments on E. coli in human serum. The researchers describe their work in a forthcoming paper in Cell Chemical Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 5, 2018 Category: Infectious Diseases Source Type: news

Aging and melanoma immunotherapy
(Source: ScienceNOW)
Source: ScienceNOW - July 5, 2018 Category: Science Authors: Yang, M. Tags: twil Source Type: news

Future health technology assessments in oncology
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. (Source: NHS Networks)
Source: NHS Networks - July 4, 2018 Category: UK Health Source Type: news

FDA-NCI Team Warns Against Single-Arm Pembrolizumab Trials in Multiple Myeloma
An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gender May Play a Role in Immunotherapy Efficacy, Further Studies Are Warranted
Immunotherapy continues to evolve as a treatment option for various cancers; however, men may see more benefit from it more than women, according to a study published in The Lancet Oncology.06/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 2, 2018 Category: Urology & Nephrology Source Type: news